日常实践中抗凝药预防卒中:依据房颤类型与临床风险因素
该嵌套病例对照研究利用两国卒中与房颤登记数据,比较个体直接口服抗凝药与维生素K拮抗剂在房颤患者中预防卒中的效果。共纳入2586例卒中病例和4810例非卒中对照。结果显示直接口服抗凝药使用者各类卒中的 odds 均低于维生素K拮抗剂使用者,且房颤类型不影响此效果。
要点
- 直接口服抗凝药在真实世界中预防卒中的效果与关键临床试验相似。
- 达比加群、利伐沙班和阿哌沙班使用者缺血性卒中风险低于维生素K拮抗剂使用者。
- 房颤类型(永久性与非永久性)不影响个体直接口服抗凝药的相对效果。
核心结论
- 在真实临床实践中,个体直接口服抗凝药预防卒中的效果与关键临床试验观察结果相似。
- 房颤类型不影响直接口服抗凝药相对于维生素K拮抗剂的卒中预防效果。
研究设计与样本
- 嵌套病例对照研究,使用两国卒中与房颤患者登记数据。
- 共纳入2586例既往有房颤的卒中病例和4810例非卒中对照房颤患者。
主要发现
- 直接口服抗凝药使用者各类卒中的 odds 低于维生素K拮抗剂使用者。
- 缺血性卒中调整匹配 OR:达比加群 0.70(95% CI, 0.50–0.98),利伐沙班 0.68(95% CI, 0.53–0.86),阿哌沙班 0.73(95% CI, 0.52–1.02)。
- 出血性卒中调整匹配 OR:达比加群 0.31(95% CI, 0.14–0.68),利伐沙班 0.64(95% CI, 0.39–1.06),阿哌沙班 0.70(95% CI, 0.33–1.49)。
临床怎么用
- 在房颤患者卒中预防中,可考虑优先选用直接口服抗凝药而非维生素K拮抗剂。
- 选择具体直接口服抗凝药时,应结合患者临床风险因素个体化决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: The objective of the study was to assess the effectiveness of individual direct oral anticoagulants versus vitamin K antagonists for primary prevention of stroke (ischemic and hemorrhagic) in routine clinical practice in patients with various clinical risk factors depending on their atrial fibrillation (AF) patterns. METHODS: A nested case-referent study was conducted using data from 2 national registries of patients with stroke and AF. Stroke cases with previous history of AF were matched to up to 2 randomly selected referent patients with AF and no stroke. The association of individual anticoagulant use with ischemic or hemorrhagic stroke was studied in patients with or without permanent AF using multivariable conditional logistic models, controlled for clinically significant risk factors and multiple other cardiovascular risk factors. RESULTS: In total, 2586 stroke cases with previous AF and 4810 nonstroke referent patients with AF were retained for the study. Direct oral anticoagulant users had lower odds of stroke of any type than vitamin K antagonist users: the adjusted-matched OR for ischemic stroke were 0.70 (95% CI, 0.50–0.98) for dabigatran, 0.68 (95% CI, 0.53–0.86) for rivaroxaban, and 0.73 (95% CI, 0.52–1.02) for apixaban while for hemorrhagic stroke they were 0.31 (95% CI, 0.14–0.68), 0.64 (95% CI, 0.39–1.06), and 0.70 (95% CI, 0.33–1.49), respectively. The effects of individual direct oral anticoagulants relative to vitamin K antagonists were similar in permanent AF and nonpermanent AF patients. CONCLUSIONS: Similar results were observed for each direct oral anticoagulant in real life as those observed in the pivotal clinical trials. The pattern of AF did not affect the outcome.
引用
- Grimaldi-Bensouda L, Le Heuzey JY, Ferrières J, et al. Stroke Prevention by Anticoagulants in Daily Practice Depending on Atrial Fibrillation Pattern and Clinical Risk Factors. Stroke. 2021. PMID: 34253047. doi:10.1161/STROKEAHA.120.032704
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。